Steward Partners Investment Advisory’s Acumen Pharmaceuticals ABOS Stock Holding History

Steward Partners Investment Advisory’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.7K	Buy	+10,000	New	+$24.7K	﹤0.01%	3281

Other funds holding ABOS

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Steward Partners Investment Advisory's ABOS Position: Q2 2026 in Review

Steward Partners Investment Advisory opened a new position in Acumen Pharmaceuticals (ABOS) in Q2 2026: 10,000 shares worth $26.7K. The stake represents ﹤0.01% of the portfolio and ranks #3281 among its holdings.

63 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

Steward Partners Investment Advisory held 10,000 shares of Acumen Pharmaceuticals worth $26.7K as of Q2 2026.
Acumen Pharmaceuticals was a new Steward Partners Investment Advisory position in Q2 2026.
Acumen Pharmaceuticals made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #3281 holding.
63 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.